SynthesisThe journal of headache and pain2026
Noradrenergic system involvement as a major driver of tension-type headache: a systematic review of the current evidence.
Synthesis in The journal of headache and pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTension-type headache (TTH) is the most prevalent primary headache disorder, affecting individuals of all ages and imposing a substantial global burden. While traditionally considered a peripheral skeletomuscular condition, current evidence suggests a prominent role for central mechanisms and neurotransmitter dysregulation. In this context, growing evidence highlights the noradrenergic system as a key contributor, both for the TTH genesis and maintenance.
methodsA systematic literature search was performed according to PRISMA guidelines. A comprehensive search of PubMed/MEDLINE and EMBASE via Scopus up to March 2024 identified studies examining the relationship between TTH and the noradrenergic system.
resultsForty-three eligible studies were included and categorized according to their focus on pathophysiology or treatment. Biochemical studies consistently reported reduced noradrenergic activity, including reduced plasma norepinephrine/epinephrine levels and dopamine-β-hydroxylase activity in TTH patients, often correlating with headache severity and chronicity. Neurophysiological and autonomic investigations further supported noradrenergic involvement, revealing altered reflex suppression, impaired sympathetic habituation, and reduced central autonomic responsiveness in TTH. Pharmacological studies indicated that medication enhancing noradrenergic transmission achieved superior clinical efficacy compared to those acting on the serotonergic system only. DISCUSSION: Overall, the body of evidence underscores the noradrenergic system’s integral role in TTH. The dysregulated noradrenergic system appears to contribute to central sensitization and impaired pain inhibition. These findings, along with the consistent efficacy of noradrenergic-targeting treatments, support a shift towards a more mechanistically specific and personalized approaches. Future research is needed to clarify the specific noradrenergic pathways implicated in TTH, in order to refine treatment strategies and enhance efficacy through precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.